Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Duloxetine in Psychological Resilience

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ages 18-65~* primary diagnosis of MDD based on Diagnostic Standard Manual(DSM-IV) criteria and assessed by the MINI International Neuropsychiatric Interview~* Montgomery-Asberg Depression Rating Scale (MADRS)score of at least 20 on baseline~* Minimum Clinical Global Impressions of Severity (CGS) severity score of 4~* Ability to provide written consent form~* A negative serum pregnancy test for women of childbearing potential~Exclusion Criteria:~* Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder or cognitive disorder due to a general medical condition~* History of substance abuse or dependence within the last 6 months~* Suicide risk or serious suicide attempt within the last year~* Clinically significant medical condition or laboratory abnormality~* Women of childbearing potential who are unwilling to practice an acceptable method of contraception~* Subjects needing concurrent use of psychotropic medications~* History of sensitivity to duloxetine~* History of failure to respond to an adequate trial of duloxetine (at least 60mg/day for 4 weeks)~* Subjects taking monoamine oxidase inhibitors (MAOIs)~* Subjects with uncontrolled narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).